

Office Action Response
Application No.: 10/789,814
Babish, J., et al.
August 7, 2006

RECEIVED
CENTRAL FAX CENTER

AUG 07 2006

AMENDMENT TO THE CLAIMS

A listing of the claims presented in this patent application appears below. This listing replaces all prior versions and listings of claims in this patent application.


1. (Previously Amended) A composition comprising a reduced isoalpha acid (RIAA) and isoalpha acid (IAA) isolated from hops, wherein the RIAA and IAA are in a ratio of about 3:1 to about 1:10 and wherein said RIAA and IAA individually comprise at least 0.1% of the composition.
2. (Original) The composition of claim 1, wherein said isoalpha acid is selected from isohumulone, isocohumulone, and isoadhumulone.
3. (Previously Amended) The composition of claim 1, wherein said reduced isoalpha acid is selected from dihydro-isohumulone, dihydro-isocohumulone, and dihydro-adhumulone.
4. (Previously Amended) A method for reducing PGE2 mediated inflammation, comprising administering a composition comprising a reduced isoalpha acid (RIAA) and isoalpha acid (IAA) isolated from hops, wherein the RIAA and IAA are in a ratio of about 3:1 to about 1: 10 and wherein said RIAA and IAA individually comprise at least 0.1% of the composition.
5. (Previously Amended) The method of claim 4, wherein said isoalpha acid is selected from isohumulone, isocohumulone, and isoadhumulone.
6. (Previously Amended) The method of claim 4, wherein said reduced isoalpha acid is selected from dihydro-isohumulone, dihydro-isocohumulone, and dihydro-adhumulone.
7. (Currently Amended) A method for reducing PGE2 mediated inflammation, comprising administering at least two compounds of Genus A having the formula:

BEST AVAILABLE COPY

(2)

BST99 1512300-1.068911.0075

Office Action Response
 Application No.: 10/789,814
 Babish, J., et al
 August 7, 2006



(Genus A),

wherein R' is selected from the group consisting of carbonyl, hydroxyl, and OOR, and OCOR, wherein R is alkyl;

and wherein R'' is selected from the group consisting of $\text{ClI}(\text{CH}_3)_2$, $\text{CH}_2\text{CH}(\text{CH}_3)_2$, and $\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$, wherein at least one compound is an RJAA and at least one compound is an IAA, wherein the two compounds are in a ratio of about 10:1 to about 1:10 and wherein said RJAA and IAA individually comprise at least 0.1% of the composition.

(3)

BST99 1512300-1.068911.0075